Advanced

Amyloid pathology in the progression to mild cognitive impairment

Insel, Philip S. LU ; Hansson, Oskar LU ; Mackin, R. Scott; Weiner, Michael; Mattsson, Niklas LU and , (2018) In Neurobiology of Aging 64. p.76-84
Abstract

The objective of this study was to determine the cognitive and functional decline and development of brain injury in individuals progressing from preclinical (β-amyloid positive cognitively normal) to prodromal Alzheimer's disease (AD) (β-amyloid positive mild cognitive impairment [MCI]), and compare this with individuals who progress to MCI in the absence of significant amyloid pathology. Seventy-five cognitively healthy participants who progressed to MCI were followed for 4 years on average and up to 10 years. We tested effects of β-amyloid (Aβ) on measures of cognition, functional status, depressive symptoms, and brain structure and metabolism. Preclinical AD subjects showed greater cognitive decline in multiple domains and increased... (More)

The objective of this study was to determine the cognitive and functional decline and development of brain injury in individuals progressing from preclinical (β-amyloid positive cognitively normal) to prodromal Alzheimer's disease (AD) (β-amyloid positive mild cognitive impairment [MCI]), and compare this with individuals who progress to MCI in the absence of significant amyloid pathology. Seventy-five cognitively healthy participants who progressed to MCI were followed for 4 years on average and up to 10 years. We tested effects of β-amyloid (Aβ) on measures of cognition, functional status, depressive symptoms, and brain structure and metabolism. Preclinical AD subjects showed greater cognitive decline in multiple domains and increased cerebrospinal fluid phosphorylated tau levels at baseline while Aβ-negative progressors showed increased rates of white matter hyperintensity accumulation and had a greater frequency of depressive symptoms at baseline. Aβ status did not influence patterns of brain atrophy, but preclinical AD subjects showed greater decline of brain metabolism than Aβ-negative progressors. Several unique features separate the transition from preclinical to prodromal AD from other causes of cognitive decline. These features may facilitate early diagnosis and treatment of AD, especially in clinical trials aimed at halting the progression from preclinical to prodromal AD.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Amyloid, Cognition, Cognitively normal, Mild cognitive impairment, MRI
in
Neurobiology of Aging
volume
64
pages
9 pages
publisher
Elsevier
external identifiers
  • scopus:85041397600
ISSN
0197-4580
DOI
10.1016/j.neurobiolaging.2017.12.018
language
English
LU publication?
yes
id
bf0d85b3-ac58-40ed-ac56-8b2ccca67210
date added to LUP
2018-02-20 13:20:35
date last changed
2018-05-29 09:20:16
@article{bf0d85b3-ac58-40ed-ac56-8b2ccca67210,
  abstract     = {<p>The objective of this study was to determine the cognitive and functional decline and development of brain injury in individuals progressing from preclinical (β-amyloid positive cognitively normal) to prodromal Alzheimer's disease (AD) (β-amyloid positive mild cognitive impairment [MCI]), and compare this with individuals who progress to MCI in the absence of significant amyloid pathology. Seventy-five cognitively healthy participants who progressed to MCI were followed for 4 years on average and up to 10 years. We tested effects of β-amyloid (Aβ) on measures of cognition, functional status, depressive symptoms, and brain structure and metabolism. Preclinical AD subjects showed greater cognitive decline in multiple domains and increased cerebrospinal fluid phosphorylated tau levels at baseline while Aβ-negative progressors showed increased rates of white matter hyperintensity accumulation and had a greater frequency of depressive symptoms at baseline. Aβ status did not influence patterns of brain atrophy, but preclinical AD subjects showed greater decline of brain metabolism than Aβ-negative progressors. Several unique features separate the transition from preclinical to prodromal AD from other causes of cognitive decline. These features may facilitate early diagnosis and treatment of AD, especially in clinical trials aimed at halting the progression from preclinical to prodromal AD.</p>},
  author       = {Insel, Philip S. and Hansson, Oskar and Mackin, R. Scott and Weiner, Michael and Mattsson, Niklas and , },
  issn         = {0197-4580},
  keyword      = {Amyloid,Cognition,Cognitively normal,Mild cognitive impairment,MRI},
  language     = {eng},
  pages        = {76--84},
  publisher    = {Elsevier},
  series       = {Neurobiology of Aging},
  title        = {Amyloid pathology in the progression to mild cognitive impairment},
  url          = {http://dx.doi.org/10.1016/j.neurobiolaging.2017.12.018},
  volume       = {64},
  year         = {2018},
}